Cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative triple treatment for rectal cancer (CET-CAPOX-RT-Phase-I/II Study): Influence on long-term survival and relevance of biomarkers.

Torsten Liersch,Lena-Christin Conradi,Thilo Sprenger,Peter Middel,Heiko Sülberg,Franz Rödel,Josef Rüschoff,Tim Beissbarth,Dirk Arnold,Claus Rödel

Cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative triple treatment for rectal cancer (CET-CAPOX-RT-Phase-I/II Study): Influence on long-term survival and relevance of biomarkers.

2017

Torsten Liersch
Lena-Christin Conradi
Thilo Sprenger
Peter Middel
Heiko Sülberg
Franz Rödel
Josef Rüschoff
Tim Beissbarth
Dirk Arnold
Claus Rödel

e14162 Background: Preoperative application of cetuximab and radiochemotherapy combined with 5-FU+oxaliplatin (CET-CAPOX-RT-phase-I/II-study) failed to increase the complete remission rate (pCR, pr...

Keywords:

Capecitabine/oxaliplatin
Colorectal cancer
Oncology
Medicine
Pathology
Oxaliplatin
Biomarker (medicine)
Internal medicine
Radiation therapy
Cetuximab
long term survival
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations